These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 30511350)

  • 21. Subjective response to antipsychotics of schizophrenia patients treated in routine clinical practice: a naturalistic comparative study.
    Ritsner M; Perelroyzen G; Ilan H; Gibel A
    J Clin Psychopharmacol; 2004 Jun; 24(3):245-54. PubMed ID: 15118477
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sex differences in the subjective tolerability of antipsychotic drugs.
    Barbui C; Nosè M; Bindman J; Schene A; Becker T; Mazzi MA; Kikkert M; Camara J; Born A; Tansella M
    J Clin Psychopharmacol; 2005 Dec; 25(6):521-6. PubMed ID: 16282831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophrenia.
    Offord S; Lin J; Mirski D; Wong B
    Adv Ther; 2013 Mar; 30(3):286-97. PubMed ID: 23483449
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Therapeutic benefit of a registered psychoeducation program on treatment adherence, objective and subjective quality of life: French pilot study for schizophrenia].
    Sauvanaud F; Kebir O; Vlasie M; Doste V; Amado I; Krebs MO
    Encephale; 2017 May; 43(3):235-240. PubMed ID: 27658989
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of the patient's subjective experience in acute neuroleptic treatment: implications for compliance and outcome.
    Awad AG; Voruganti LN; Heslegrave RJ; Hogan TP
    Int Clin Psychopharmacol; 1996 May; 11 Suppl 2():55-9. PubMed ID: 8803661
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life.
    Voruganti L; Cortese L; Oyewumi L; Cernovsky Z; Zirul S; Awad A
    Schizophr Res; 2000 Jun; 43(2-3):135-45. PubMed ID: 10858632
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antipsychotics and the quality of life of schizophrenic patients.
    Loga-Zec S; Loga S
    Psychiatr Danub; 2010 Dec; 22(4):495-7. PubMed ID: 21169888
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adherence to antipsychotics and cardiometabolic medication: association with health care utilization and costs.
    Hansen RA; Maciejewski M; Yu-Isenberg K; Farley JF
    Psychiatr Serv; 2012 Sep; 63(9):920-8. PubMed ID: 22706887
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.
    Olivares JM; Rodriguez-Martinez A; Burón JA; Alonso-Escolano D; Rodriguez-Morales A;
    Appl Health Econ Health Policy; 2008; 6(1):41-53. PubMed ID: 18774869
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Challenges in the design and conduct of controlled clinical effectiveness trials in schizophrenia.
    Rosenheck RA; Krystal JH; Lew R; Barnett PG; Thwin SS; Fiore L; Valley D; Huang GD; Neal C; Vertrees JE; Liang MH;
    Clin Trials; 2011 Apr; 8(2):196-204. PubMed ID: 21270143
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight.
    Freudenreich O; Cather C; Evins AE; Henderson DC; Goff DC
    J Clin Psychiatry; 2004 Oct; 65(10):1372-6. PubMed ID: 15491241
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study.
    Kerwin R; Millet B; Herman E; Banki CM; Lublin H; Pans M; Hanssens L; L'Italien G; McQuade RD; Beuzen JN
    Eur Psychiatry; 2007 Oct; 22(7):433-43. PubMed ID: 17555947
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Facilitating compliance with antipsychotic medication.
    Marder SR
    J Clin Psychiatry; 1998; 59 Suppl 3():21-5. PubMed ID: 9541334
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of atypical antipsychotic medications on psychosocial outcomes.
    Corrigan PW; Reinke RR; Landsberger SA; Charate A; Toombs GA
    Schizophr Res; 2003 Sep; 63(1-2):97-101. PubMed ID: 12892863
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life.
    Lambert M; Naber D
    CNS Drugs; 2004; 18 Suppl 2():5-17; discussion 41-3. PubMed ID: 15461312
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Subjective tolerability of antipsychotic medications and the emerging science of subjective tolerability disorders.
    Awad AG
    Expert Rev Pharmacoecon Outcomes Res; 2010 Feb; 10(1):1-4. PubMed ID: 20121558
    [No Abstract]   [Full Text] [Related]  

  • 39. Dysphoric subjective response to neuroleptics in schizophrenia: relationship to extrapyramidal side effects and symptomatology.
    Gervin M; Browne S; Garavan J; Roe M; Larkin C; O'Callaghan E
    Eur Psychiatry; 1999 Nov; 14(7):405-9. PubMed ID: 10683626
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antipsychotic medication, functional outcome and quality of life in schizophrenia: focus on amisulpride.
    Nuss P; Tessier C
    Curr Med Res Opin; 2010 Apr; 26(4):787-801. PubMed ID: 20121655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.